Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Average Rating of “Hold” by Brokerages

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) have been assigned a consensus rating of “Hold” from the eight ratings firms that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation, one has issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $4.94.

IRWD has been the subject of several recent research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Ironwood Pharmaceuticals in a research note on Wednesday, October 8th. Zacks Research upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 6th. Finally, Wall Street Zen upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 9th.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Several institutional investors have recently modified their holdings of IRWD. Armistice Capital LLC lifted its position in shares of Ironwood Pharmaceuticals by 44.7% during the 1st quarter. Armistice Capital LLC now owns 13,700,000 shares of the biotechnology company’s stock worth $20,139,000 after purchasing an additional 4,232,000 shares during the last quarter. Millennium Management LLC increased its holdings in shares of Ironwood Pharmaceuticals by 186.6% in the 1st quarter. Millennium Management LLC now owns 6,359,682 shares of the biotechnology company’s stock valued at $9,349,000 after acquiring an additional 4,140,439 shares during the last quarter. Acadian Asset Management LLC increased its holdings in shares of Ironwood Pharmaceuticals by 147.6% in the 2nd quarter. Acadian Asset Management LLC now owns 6,549,687 shares of the biotechnology company’s stock valued at $4,685,000 after acquiring an additional 3,904,498 shares during the last quarter. AQR Capital Management LLC increased its holdings in shares of Ironwood Pharmaceuticals by 144.3% in the 2nd quarter. AQR Capital Management LLC now owns 6,165,637 shares of the biotechnology company’s stock valued at $4,422,000 after acquiring an additional 3,641,762 shares during the last quarter. Finally, Marshall Wace LLP increased its holdings in shares of Ironwood Pharmaceuticals by 616.3% in the 2nd quarter. Marshall Wace LLP now owns 3,993,557 shares of the biotechnology company’s stock valued at $2,875,000 after acquiring an additional 3,436,036 shares during the last quarter.

Ironwood Pharmaceuticals Trading Down 3.1%

IRWD opened at $1.86 on Tuesday. The stock’s 50-day moving average price is $1.43 and its 200 day moving average price is $1.01. Ironwood Pharmaceuticals has a 12-month low of $0.53 and a 12-month high of $5.13. The firm has a market cap of $302.13 million, a price-to-earnings ratio of -37.19 and a beta of 0.30.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings data on Thursday, August 7th. The biotechnology company reported $0.14 EPS for the quarter, beating the consensus estimate of ($0.02) by $0.16. Ironwood Pharmaceuticals had a negative net margin of 2.25% and a negative return on equity of 2.46%. The business had revenue of $85.24 million during the quarter, compared to analyst estimates of $62.02 million. Ironwood Pharmaceuticals has set its FY 2025 guidance at EPS. On average, research analysts forecast that Ironwood Pharmaceuticals will post 0.1 earnings per share for the current year.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.